MedPageToday
MedPage Today) — SAN DIEGO — Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared with standard first-line…
Read More
Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP
Buffy Schildgen
00:24
MedPage Today) — SAN DIEGO — Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared with standard first-line…
